As Clinical Research Evolves, We Cannot Lose the Human Side

For more than 20 years, I have worked in clinical research, and today I lead global clinical trials across countries, cultures, regulatory environments, and healthcare systems. I am also a published author.

At first, those two parts of my life may seem very different. But both have taught me the same lesson: numbers rarely tell the entire story. In one of my essays, I explored a deceptively simple question: What is more important—health or happiness? There is no simple answer. But the question has stayed with me because it reminds me why clinical research exists in the first place.

We speak every day about endpoints, timelines, data quality, regulatory requirements, enrollment, and operational delivery. All are essential. Yet behind every endpoint is a person hoping for something much more personal: another birthday, another dinner with family, another ordinary morning when illness is not the first thing on their mind. That is the human side of clinical research and as our industry becomes more technologically sophisticated and globally complex, I believe protecting it must become even more intentional.

Over the next 12 to 24 months, one meaningful change I would lead from my current role is a more harmonized approach to global trial delivery—identifying regulatory differences earlier and building those realities into trial strategy from the beginning. Leading global trials has shown me how differently one protocol can travel through the world. Science may be the same. The investigational product may be the same. The responsibility to protect participants is the same. Yet regulatory interpretations, submission requirements, privacy expectations, data-localization rules, timelines, and operational processes can differ substantially across jurisdictions. Those differences often exist for legitimate reasons. I am not suggesting that every country should have identical regulations. Harmonization is not uniformity. Instead, it means creating greater alignment around the principles that should transcend borders: participant safety, meaningful informed consent, ethical conduct, scientific rigor, data integrity, transparency, and respect for every individual who volunteers for research.

True harmonization depends on collaboration. Sponsors, regulators, investigators, ethics committees, and patients can identify practical challenges before they delay study start-up or affect participant experience.

Technology can help us move closer to that goal. Emerging technologies, including artificial intelligence, can help clinical teams identify regulatory differences earlier, map evolving requirements, recognize potential conflicts, and anticipate operational impacts before they become barriers. Used responsibly, these tools can allow us to spend less time discovering differences late and more time designing trials that account for them from the beginning. But in reality,  technology should inform human judgment, never replace it. Global clinical trials do not operate separately from the world around them. Political instability can affect site access. Sanctions and export controls can disrupt the movement of investigational products and equipment. Supply-chain interruptions can threaten continuity. Privacy and data-localization requirements influence how information moves across borders.

This is precisely why greater global alignment must still leave room for local knowledge. A consistent standard for participant protection should coexist with an understanding of the communities in which research is conducted. Local regulatory experts, investigators, research sites, and patient communities should not simply receive a global strategy; their perspectives should help shape how that strategy is implemented. Standardization improves consistency and efficiency, but excessive standardization can overlook important local realities. Technology provides extraordinary visibility and speed, but increased collection and movement of information create equally important responsibilities around privacy, cybersecurity, and informed consent. Our challenge is not to choose one over the other. It is to build a clinical research environment capable of balancing both.

As my own role evolves, I see myself spending less time reacting to complexity and more time anticipating it—bringing clinical operations, regulatory strategy, technology, and local expertise together earlier. I want technology to tell us where to look, but I still want people to tell us what it means. Because a system can identify a delay. It cannot fully understand a community’s hesitation. An algorithm can recognize a pattern. It cannot build trust with a participant. Artificial intelligence can process enormous amounts of information, but it cannot replace the responsibility we carry when another human being entrusts us with their health, their information, and sometimes their hope.

That responsibility remains ours. I would measure the success of this approach through shorter and more predictable start-up timelines, fewer avoidable regulatory delays, stronger data quality, fewer recurring protocol deviations, improved issue-resolution times, greater inspection readiness, and fewer operational disruptions caused by requirements that could have been identified earlier. I would also evaluate recruitment, retention, site feedback, and representation of diverse communities.

But there is another measure I would never want us to forget: Did we make it easier for people to participate in research without compromising their safety, privacy, dignity, or trust? Clinical research will continue to evolve. Artificial intelligence will become more capable. Digital technologies will continue to transform how we design, monitor, and manage studies. Our ability to analyze data, predict risk, and connect research across borders will continue to expand but progress should not be measured by how faster we can move. It should also be measured by how well we preserve what technology cannot reproduce: human judgment, human connection, empathy, and trust.

When I once asked whether health or happiness matters more, I was asking a profoundly human question—one that cannot be answered by a dataset alone. Perhaps clinical research, at its very best, exists somewhere within that question. The people who participate in our trials are not searching for an endpoint. They are searching for more life, more time with the people they love, and the possibility of living that life well. Regulations protect them. Science guides us. Technology can help us reach them. Yet none of these achievements has lasting value unless they strengthen the trust that patients place in us when they volunteer for research.

Clinical research will continue to evolve, but its greatest innovation will always be our ability to combine scientific excellence with compassion. Humanity must remain the reason we pursue better science, better technology, and better global collaboration.

iStock image

The post As Clinical Research Evolves, We Cannot Lose the Human Side appeared first on The Good Men Project.